Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.50 |
| ▸ | KHK | P50053 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4222804 | 0.98 | HPGDS (0.51) | HPGDSMAPK14MAPK13KHKABL1 | |
| SCHEMBL4219336 | 0.96 | HPGDS (0.55) | HPGDSMAPK14MAPK13KHKABL1 | |
| SCHEMBL4219269 | 0.90 | KHK (0.56) | HPGDSMAPK14MAPK13KHKCYP2C9 | |
| SCHEMBL4225219 | 0.89 | HPGDS (0.53) | HPGDSMAPK14MAPK13CYP2C9 | |
| SCHEMBL4219621 | 0.88 | MAPK14 (0.51) | HPGDSMAPK14MAPK13ABL1CYP2C9 | |
| SCHEMBL4225251 | 0.86 | MAPK13 (0.53) | HPGDSMAPK14MAPK13CYP2C9 | |
| SCHEMBL4230100 | 0.86 | NR3C1 (0.51) | MAPK14MAPK13 | |
| SCHEMBL4215115 | 0.85 | NR3C1 (0.50) | MAPK14 | |
| SCHEMBL4217133 | 0.85 | MAPK13 (0.50) | HPGDSMAPK14MAPK13CYP2C9 | |
| SCHEMBL4227265 | 0.85 | MAPK14 (0.55) | HPGDSMAPK14CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | HPGDS 122/4885MAPK14 19/4885MAPK13 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.